MRI-guided Ultrasound Treatment for Prostate Cancer
Author Information
Author(s): Anttinen Mikael, Mäkelä Pietari, Nurminen Pertti, Pärssinen Heikki, Malaspina Simona, Sainio Teija, Högerman Mikael, Taimen Pekka, Blanco Sequeiros Roberto, Boström Peter J.
Primary Institution: University of Turku and Turku University Hospital, Turku, Finland
Hypothesis
Salvage magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (sTULSA) is effective for localized radiorecurrent prostate cancer.
Conclusion
sTULSA is effective for radiorecurrent prostate cancer, but significant genitourinary toxicity is a concern.
Supporting Evidence
- 89% of patients showed no cancer in the targeted area at 12 months.
- Median PSA reduction was 95% at 12 months.
- 56% of patients experienced adverse events, with severe genitourinary toxicity in 28%.
Takeaway
This study looked at a new treatment for prostate cancer that came back after radiation. It worked well for most patients, but some had serious side effects.
Methodology
This phase 2 study involved men with biochemically relapsed prostate cancer who underwent MRI-guided transurethral ultrasound ablation, with follow-up assessments at 12 months.
Potential Biases
Potential bias due to the single-center study design.
Limitations
Single-arm design and moderate sample size.
Participant Demographics
Median age of participants was 73 years, with 41% receiving hormonal therapy.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% (0.93–1.00)
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website